Up-regulation of vascular endothelial growth factor production by iron chelators

Cancer Research

Volumn 56, Issue 16, 1996, Pages 3747-3751

  Beerepoot, Laurens V ^a   Shima, David T ^b   Kuroki, Masatoshi ^b   Yeo, Kiang Teck ^c   Voest, Emile E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,10 PHENANTHROLINE; DEFEROXAMINE; IRON; IRON CHELATE; MESSENGER RNA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IRON CHELATION; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; RETINA MACULA EDEMA; TUMOR VASCULARIZATION;

ANIMALS; CELL LINE; DEFEROXAMINE; ENDOTHELIAL GROWTH FACTORS; HUMANS; IRON CHELATING AGENTS; LYMPHOKINES; MICE; RATS; RNA, MESSENGER; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0029742532     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Voest, E. E., Vreugdenhil, G., and Marx, J J. M. Iron-chelating agents in non-iron overload conditions Ann. Intern. Med , 120 490-499, 1994.
2. Free radicals as useful species. In. B Halliwell and J. M. C. Gutteridge (eds.), Free Radicals in Biology and Medicine, Ed. 2, pp 366-368. Oxford, United Kingdom. Clarendon Press, 1989
3. Page Faulk, W., Hsi, B-L , and Stevens, P J. Transfenin and transferrin receptors in carcinoma of the breast. Lancet. 2: 390-392, 1980.
4. Cazzola, M., Bergamaschi, G., Dezza, L , and Arosio, P. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood, 75: 1903-1919, 1990.
5. Blatt, J., and Stitely, S. Antineuroblastoma activity of desferoxamine in human cell lines. Cancer Res , 47: 1749-1750, 1987.
6. Voest, E E., Rooth, H., Neijt, J. P , van Asbeck, B. S., and Marx, J. J. M. The in vitro response of human tumour cells to desferrioxamme is growth medium dependent. Cell Prolif., 26: 77-88, 1993
7. Lundberg, J. H , and Chitambar, C R. Interaction of gallium nitrate with fludarabine and iron chelators: effects on the proliferation of human leukemic HL60 cells. Cancer Res., 50. 6466-6470, 1990
8. Taetle, R , and Honeysett, J. M Effects of monoclonal anti-trsnsferrin receptor antibodies on in vitro growth of human solid tumor cells. Cancer Res., 47: 2040-2044, 1987
9. Barry, M., Flynn, D. M , Letsky, E A , and Ridson, R. A. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology and clinical progress. Br. Med. J., 2: 16-20, 1974.
10. Olivieri, N. F., Buncic, J. R., Chew, E, Gallant, T, Harrison, R V., Keenan, N., Logan, W., Mitchell, D., Ricci, G., Skarf, B., Taylor, M., and Freedman, M. H. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions N Engl. J. Med., 314: 869-873, 1986.
11. Guerin, A , London, G., Marchais, S., Metivier, F., and Pelisse, J-M. Acute deafness and desferrioxamine. Lancet. 2: 39-40, 1985
12. Porter, J. B., East, C. A., Jaswon, M. S , and Huehns, E. R Audiometric abnormalities in thalassemia: risk factors associated with the use of desferrioxamine (Abstract) Br J Haematol., 69: 107, 1988.
13. Castriota Scanderbeg, A, Izzi, G C., Butturini, A., and Benaglia, G. Pulmonary syndrome and intravenous high-dose desferrioxamine Lancet, 336: 1511, 1990
14. Weitman, S. D , Buchanan, G. R., and Kamen, B. A Pulmonary toxicity of deferoxamine in children with advanced cancer. J. Natl Cancer Inst., 83: 1834-1835, 1991.
15. Voest, E. E., Neijt, J P., Keunen, J. E. E., Dekker, A. W., van Asbeck, B. S., Nortier, J. W. R., Ros, F. E , and Marx, J. J. M A Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. Cancer Chemother. Pharmacol , 31: 357-362, 1993.
16. Polson, R. J , Jawed, A , Bomford, A, Berry, H., and Williams, R. Treatment of rheumatoid arthritis with desferrioxamine' relation between stores of iron before treatment and side effects. Br. Med. J . 297: 448, 1985.
17. Senger, D R , Galli, S. J., Dvorak, A. M., Peruzzi, C. A , Harvey, V S., and Dvorak, H F Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (Washington DC), 2/9- 983-985, 1983.
18. 2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res., 50 1774-1778, 1990.
19. Wang, G. L., and Semenza, G L. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood, 82: 3610-3615, 1993.
20. Goldberg, M. A., and Schneider, T. J. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin J Biol Chem., 269: 4355-4359, 1994
21. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction Anal Biochem., 162: 156-159, 1987.
22. Yeo, K-T., Sioussat, T M., Faix, J. D, Senger, D. R., and Yeo, T-K Development of time-resolved immunofluorometric assay of vascular permeability factor Clin. Chem. 38: 71-75, 1992
23. Roberts, W. G , and Palade, G. E Increased capillary permeability and endothelial fenestration induced by vascular endothelial growth factor J Cell Sci., 108: 2369-2379, 1995.
24. Leung, D. W , Cachianes, G , Kuang, W. J , Goeddel, D. V., and Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (Washington DC), 246: 1306-1309, 1989
25. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med , 1: 27-31, 1995
26. Folkman, J Tumor angiogenesis In: J Mendelsohn, P Howley, L. A. Liotta, and M. Israel (eds ), The Molecular Basis of Cancer, pp 206-232. Philadelphia W B. Saunders Co , 1995
27. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S , and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature (Lond.), 362: 841-844, 1993.
28. Millauer, B., Shawver, L K , Plate, K. H , Risau, W., and Ullrich, A. Ghoblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (Lond.), 367: 576-579, 1994.
29. Shweiki, D , Itin, A., Soffer, D., and Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond). 359: 843-845, 1992
30. Shima, D. T. Deutsch, U., and D'Amore, P A. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability FEBS Lett. 370: 203-208, 1995
31. Finkenzeller, G., Marme, D., Weich, H. A , and Hug, H. Platelet-derived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Cancer Res , 52: 4821-4823, 1992.
32. Kuroki, M., Beerepoot, L V., Voest, E. E, and Adamis, A. P. Regulation of VEGF mRNA expression by reactive oxygen inter-mediates (Abstract 4113). Invest. Ophthalmol Visual Sci., 36, S895, 1995.
33. Cullinan-Bove, K., and Koos, R. D. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology. 133: 829-837, 1993.
34. Florence, A T., and Attwood, D. Physicochemical Principles of Pharmacy, pp. 329-331 London, United Kingdom: Macmillan Publishing Co, 1988.
35. O'Halloran, T. V Transition metals in control of gene expression. Science (Washington DC), 261 715-725, 1993.
36. Goldberg, M. A., Dunning, S P , and Bunn, H F. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science (Washington DC), 242: 1412-1415, 1988.
37. Donfrancesco, A., Deb, G , Dominici, C , Pileggi, D., Castello, M. A., and Helson, L. Effects of a single course of deferoxamine in neuroblastoma patients Cancer Res., 50: 4929-4930, 1990.
38. Estrov, Z., Tawa, A., Wang, X-H., Dube, I. D , Sulh, H , Cohen, A , Gelfland, E. W., and Freedman, M. H In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood, 69: 757-761, 1987.
39. Dezza, L., Cazzola, M., Danova, M., Carlo-Stella, C., Bergamaschi, G , and Brugnatelli, S. Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies Leukemia (Baltimore), 3: 104-107, 1989.
40. Dreier, R , Kemp, P., Forest, P., Stegink, L., and See, W Phase II study of deferoxamine in patients with hormone-refractory metastatic prostate cancer. Proc. Am. Soc Clin. Oncol Annu. Meet., 14: 688, 1995.
41. Speyer, J. L., Green, M. D , Kramer, E , Rey, M., Sanger, J., Ward, C , Dubin, N., Ferrans, V., Stecy, P , Zeleniuch-Jacquotte, A., Wemz, J., Feit, F., Slater, W., Blum, R., and Muggia, F. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N. Engl. J Med , 319: 745-752, 1988